News
MyChesCo on MSN11h
AstraZeneca’s IMFINZI® Demonstrates Promising Results in POTOMAC Phase III Trial for High-Risk NMIBCAstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® ...
The analysis by Ontada tracked testing rates withing the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback